{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Welcure Drugs & Pharmaceuticals Ltd
Welcure Drugs & Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses
Welcure Drugs & Pharmaceuticals Ltd is currently experiencing significant selling pressure, with the stock registering a sharp decline and only sell orders visible in the market queue. This distress selling signals a challenging phase for the company amid broader market fluctuations.
Welcure Drugs & Pharmaceuticals Surges with Unprecedented Buying Interest
Welcure Drugs & Pharmaceuticals has captured market attention with an extraordinary surge in buying activity, registering a 3.64% gain today while the broader Sensex declined by 0.25%. The stock’s unique position of having only buy orders in the queue signals a potential multi-day upper circuit scenario, reflecting robust investor enthusiasm amid a challenging market backdrop.
Welcure Drugs & Pharmaceuticals Hits Upper Circuit Amidst Unprecedented Buying Interest
Welcure Drugs & Pharmaceuticals Ltd has witnessed extraordinary buying momentum today, with the stock hitting its upper circuit and registering only buy orders in the queue. This rare market phenomenon highlights intense demand and a complete absence of sellers, signalling a potential multi-day circuit scenario for the pharmaceutical company.
Welcure Drugs & Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses
Welcure Drugs & Pharmaceuticals Ltd has encountered significant selling pressure, with the stock registering a sharp decline and exhibiting a complete absence of buyers on the trading day. This distress selling signals a challenging phase for the company amid a broader market environment where the Sensex remains steady.
Why is Welcure Drugs falling/rising?
On 21-Nov, Welcure Drugs & Pharmaceuticals Ltd recorded a modest price increase of 3.57%, closing at ₹0.58, marking a continuation of a short-term recovery despite a challenging longer-term performance backdrop.
Welcure Drugs & Pharmaceuticals Hits Upper Circuit Amidst Unprecedented Buying Interest
Welcure Drugs & Pharmaceuticals Ltd has witnessed extraordinary buying momentum, hitting the upper circuit with only buy orders in the queue. This rare market phenomenon highlights intense demand and the absence of sellers, signalling a potential multi-day circuit scenario for the pharmaceutical company’s stock.
Welcure Drugs & Pharmaceuticals Hits Upper Circuit Amidst Unprecedented Buying Interest
Welcure Drugs & Pharmaceuticals Ltd has witnessed extraordinary buying momentum today, with the stock hitting its upper circuit and registering only buy orders in the queue. This rare market phenomenon highlights intense demand and a complete absence of sellers, signalling a potential multi-day circuit scenario for the microcap pharmaceutical player.
Why is Welcure Drugs falling/rising?
As of 19-Nov, Welcure Drugs & Pharmaceuticals Ltd is facing a significant decline in its stock price, currently at 0.54, with a 3.57% decrease. The stock has lost 15.63% over the last four days and 27.03% over the past month, underperforming compared to the Sensex, which has gained 0.85% in the same period.
Welcure Drugs & Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses
Welcure Drugs & Pharmaceuticals Ltd is currently experiencing significant selling pressure, marked by a lower circuit scenario with only sell orders in the queue. The stock has recorded consecutive declines over the past four days, reflecting distress selling signals and a lack of buyer interest in the Pharmaceuticals & Biotechnology sector.
Welcure Drugs Faces Significant Selling Pressure with 24.32% Monthly Loss and 47.45% Three-Month Decline
Welcure Drugs & Pharmaceuticals Ltd is experiencing notable selling pressure, with the stock declining significantly over various time frames. It has faced consecutive losses, underperforming the Sensex, and is trading below multiple moving averages, reflecting ongoing challenges and diminished buyer interest in the microcap pharmaceutical sector.
Why is Welcure Drugs falling/rising?
As of 17-Nov, Welcure Drugs & Pharmaceuticals Ltd's stock price is declining at 0.58, down 4.92%, and has underperformed its sector by 5.2%. The stock is trading below all major moving averages, indicating a bearish trend, and has a year-to-date decline of 44.78% compared to the Sensex's gain of 8.72%.
Welcure Drugs & Pharmaceuticals Faces Significant Selling Pressure, Declines 4.92% Amid Ongoing Losses
Welcure Drugs & Pharmaceuticals Ltd is experiencing notable selling pressure, with significant declines over various time frames, including a 21.62% drop in the past month and a 44.78% fall year-to-date. The stock is trading below key moving averages, reflecting ongoing challenges in the pharmaceuticals sector.
Welcure Drugs Q2 FY26: Sharp Revenue Decline Raises Sustainability Concerns
Welcure Drugs & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹75.00 crores, reported a perplexing quarterly performance for Q2 FY26, with net profit declining 63.52% quarter-on-quarter to ₹8.50 crores despite revenue volatility that has raised questions about business sustainability. The stock has extended its bearish trend, falling 4.69% following the results announcement and trading at ₹0.61, down 57.34% from its 52-week high of ₹1.43.
How has been the historical performance of Welcure Drugs?
Welcure Drugs experienced a significant turnaround in the fiscal year ending March 2025, reporting net sales of 24.55 crore and a profit after tax of 2.17 crore, compared to losses in the previous year. This marked its first year of substantial revenue generation and profitability, with improved operating and profit margins.
Welcure Drugs & Pharmaceuticals Faces Selling Pressure, Stock Declines 4.69% Amid Significant Losses
Welcure Drugs & Pharmaceuticals Ltd is experiencing significant selling pressure, with a notable decline following six days of gains. The stock has underperformed compared to the Sensex over various timeframes, indicating a bearish trend. Current prices are above the 5-day moving average but below longer-term averages.
How has been the historical performance of Welcure Drugs?
Welcure Drugs experienced a significant turnaround in March 2025, achieving net sales of 24.55 crore and an operating profit of 2.79 crore, compared to previous losses. Profit after tax reached 2.17 crore, with earnings per share improving to 0.19.
Why is Welcure Drugs falling/rising?
As of 13-Nov, Welcure Drugs & Pharmaceuticals Ltd is seeing a price increase to 0.64, up 4.92% today, with a strong short-term performance of +20.75% over the past week, despite a year-to-date decline of 39.07%. Increased investor interest is noted, with delivery volume rising significantly, indicating potential for recovery in the short term.
Welcure Drugs & Pharmaceuticals Rises 4.92%, Marks Sixth Consecutive Day of Gains at 25.49%
Welcure Drugs & Pharmaceuticals Ltd is experiencing notable buying activity, with a recent six-day gain of 25.49%. Despite this short-term surge, the stock has faced challenges over longer periods, showing declines of 11.66% in the past month and 39.07% year-to-date, contrasting with broader market trends.
Welcure Drugs & Pharmaceuticals Ltd Rises 3.39%, Marks Fifth Consecutive Day of Gains
Welcure Drugs & Pharmaceuticals Ltd is experiencing notable buying activity, with a recent performance indicating a shift in market sentiment. Despite previous declines, the stock has shown significant gains over the past week, reflecting heightened buyer interest and a potential short-term recovery amid longer-term challenges.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
